Expression of circ_0025033 in ovarian cancer and its clinical significance
Objective To investigate the value of plasma cyclic RNA 0025033(circ_0025033)in diagnosis and treatment response prediction of ovarian cancer.Methods One hundred and sixty-five patients with ovarian tumor from September 2020 to June 2022 were collected as the study objects,including 100 cases of epithelial ovarian cancer(EOC),30 cases of benign ovarian tumor and 35 cases of borderline tumor.Thirty healthy volunteers during the same period were selected as the control group.The expression of circ_0025033 was detected in venous blood.Receiver operating characteristic(ROC)curve was used to evaluate the efficacy of circ_0025033 expression in diagnosing EOC.According to the treatment response,58 patients with EOC were divided into chemotherapy sensitive group(n=32)and chemotherapy resistant group(n=26).The value of plasma circ_0025033 in predicting EOC chemotherapy response before treatment was analyzed.Results The plasma circ_0025033 level of EOC patients was significantly higher than that of healthy subjects,borderline tumors and benign ovarian tumors(P<0.05).The area under the curve(AUC)of plasma circ_0025033 for diagnosing EOC in healthy volunteers,benign tumors and borderline tumors were 0.781(95%CI:0.698-0.864),0.679(95%CI:0.579-0.779)and 0.731(95%CI:0.636-0.826),respectively.FIGO stage and lymph node metastasis were correlated with circ_0025033 level before chemotherapy(P<0.05).The circ_0025033 level was correlated with FIGO stage and ascites after chemotherapy(P<0.05).ROC curve results showed that the optimal cut-off value was 2.685.AUC of plasma circ_0025033 before treatment to predict chemotherapy sensitivity of EOC patients was 0.941(95%CI:0.884-0.998,P<0.001),and sensitivity and specificity were 0.846 and 0.937,respectively.Conclusion Plasma circ_0025033 may be a biomarker for the diagnosis of EOC and the prediction of chemotherapy efficacy before treatment.
NETL
NSTL
万方数据
